|
Mechanismfungal CYP51A1 inhibitors |
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.US |
First Approval Date31 Dec 1987 |
Target- |
MechanismDNA synthesis inhibitors |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
Solubilized Metronidazole And/oR Terconazole Gels Intra-Vaginal Efficacy and Safety
The purpose of this study is to evaluate the safety and efficacy of metronidazole gel in the treatment of vaginal infections.
Solubilized Metronidazole And/oR Terconazole Gels Intra-Vaginal Efficacy and Safety
The purpose of this study is to evaluate the safety and efficacy of terconazole/metronidazole gel in the treatment of vaginal infections
Solubilized Metronidazole And/oR Terconazole Gels Intra-Vaginal Efficacy and Safety
The purpose of this study is to evaluate the safety and efficacy of terconazole gel in the treatment of vaginal infections
100 Clinical Results associated with Curatek Pharmaceuticals, LLC
0 Patents (Medical) associated with Curatek Pharmaceuticals, LLC
100 Deals associated with Curatek Pharmaceuticals, LLC
100 Translational Medicine associated with Curatek Pharmaceuticals, LLC